Insurance Co Name

Insurance Co Address

June 23, 2023

Re: Name: Patient Name

DOB: Enter date of birth

Account #: Enter insurance company account number

To whom it may concern:

This letter is to support an appeal for choose a reason plasmapheresis for my patient enter patient name. Enter patient name is experiencing a severe exacerbation of multiple sclerosis with acute neurological deficits choose a rationale.

**Include the following two paragraphs if your patient has relapse symptoms refractory to treatment with high-dose corticosteroid treatment (delete if not).**

Enter patient name suffered an acute exacerbation of multiple sclerosis on enter date, with symptoms including enter symptoms*.* Standard high-dose corticosteroid therapy of enter dose, route of administration, and duration was initiated on enter date , with no improvement. On enter date, I prescribed a course of plasmapheresis as it is medically necessary to treat these refractory symptoms.

The [American Academy of Neurology’s *Evidence-based Guideline Update: Plasmapheresis in neurologic disorders*](https://www.ncbi.nlm.nih.gov/pubmed/21242498) states that plasmapheresis is probably effective and should be considered as second-line treatment for steroid-resistant exacerbations in relapsing forms of MS.1

**Include the following paragraph if your patient has a contraindication to using high-dose corticosteroids for relapse management (delete previous two paragraphs and reference if not relevant).**

Enter patient name suffered an acute exacerbation of multiple sclerosis on enter date, with symptoms including enter symptoms. Enter patient name has contraindications to using high-dose corticosteroids for the management of these symptoms. Enter contraindications here.

Plasmapheresis is medically necessary for my patient, enter patient name, as enter patient name choose a rationale . I respectfully request that you choose consider/reconsider coverage for this patient. Thank you in advance for your timely response.

Sincerely,

Click or tap here to enter text.

Click or tap here to enter text.

Click or tap here to enter text.

1Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. (2011). Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*, 76(3), 294-300. DOI: 10.1212/WNL.0b013e318207b1f6